# Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

> **NCT00049582** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- de Novo Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Previously Treated Myelodysplastic Syndromes
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndromes
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** decitabine
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00049582
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-09
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049582, "Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00049582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*